Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica

KEISUKE HAGIHARA, ICHIRO KAWASE, TOSHIO TANAKA and TADAMITSU KISHIMOTO
The Journal of Rheumatology May 2010, 37 (5) 1075-1076; DOI: https://doi.org/10.3899/jrheum.091185
KEISUKE HAGIHARA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ICHIRO KAWASE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TOSHIO TANAKA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ttanak@imed3.med.osaka-u.ac.jp
TADAMITSU KISHIMOTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

Polymyalgia rheumatica (PMR) is a chronic inflammatory disorder of unknown etiology that affects the elderly1. The disease is characterized by aching and morning stiffness in the shoulders, neck, and pelvic girdles. Although the pathogenesis of PMR remains unknown, overproduction of proinflammatory cytokines has been demonstrated to contribute to its development1,2. Corticosteroids constitute the preferred treatment for PMR and prednisolone 10–20 mg/day is usually adequate. But when prednisolone is tapered, the disease sometimes flares and continuous treatment with corticosteroids is needed. As alternative therapies, methotrexate and tumor necrosis factor (TNF)-blocking agents showed promise, but the use of these drugs remains controversial1,3. Since interleukin 6 (IL-6) has been shown to play a major role in sustaining disease activity in PMR1,2,4–6, treatment of a patient with PMR refractory to corticosteroids was initiated with the humanized anti-IL-6 receptor antibody tocilizumab7.

A 65-year-old woman presented in 2002 with morning stiffness, aching of the shoulders, myalgia in the upper limbs, and difficulty with elevating the upper limbs. Although C-reactive protein (CRP) was highly elevated, creatine phosphokinase was within normal range, and antinuclear, antineutrophil cytoplasmic, and anti-Jo1 antibodies and rheumatoid factor were all negative. She had been diagnosed with PMR at another hospital, where treatment with prednisolone 20 mg/day had resulted in prompt disappearance of clinical symptoms. But when prednisolone was tapered to 8–10 mg/day, the disease flared repeatedly (Figure 1) and was made worse by diabetes mellitus, hypertension, and osteoporosis. She was referred to our hospital in 2006. Informed consent by the patient and approval by the Ethics Committee of Osaka University Hospital were obtained for the injection of tocilizumab 8 mg/kg every 4 weeks starting in October 2008, in combination with oral prednisolone 10 mg/day. Prior to the treatment, she felt morning stiffness for 3 hours and pain in shoulders, pelvic girdle, and knee joints. Edema in the lower limbs was also observed. Serum levels of CRP and serum amyloid A (SAA) were elevated to 0.62 mg/dl (normal < 0.2 mg/dl) and 86 μg/ml (normal < 8 μg/ml), respectively. Serum IL-6 level was 4.7 pg/ml. Her PMR activity score (PMR-AS), which consists of CRP value, visual analog scale (0–10) of patient’s pain and physician’s assessment of disease activity, duration of morning stiffness, and ability to elevate the upper limbs8, was 22.12, indicating high disease activity. After 1 injection of tocilizumab, serum CRP and SAA levels became normal and pain in the shoulders and pelvic girdle improved, but morning stiffness persisted. After 5 infusions of tocilizumab, morning stiffness disappeared and the PMR-AS decreased to 0.74, indicating remission according to the PMR-AS criteria9. Continued tocilizumab treatment ended clinical symptoms, so that prednisolone could be reduced to 6 mg/day (Figure 1).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Clinical course of PMR. Administration of tocilizumab was started on Day 0. Changes in prednisolone (PSL) dose, serum levels of C-reactive protein (CRP), serum amyloid A (SAA), and the PMR activity score (PMR-AS) are indicated.

To our knowledge, this is the first study to demonstrate the ameliorative effect of tocilizumab on symptoms caused by PMR. Increased serum concentrations of proinflammatory cytokines, including IL-1ß, TNF-α, and IL-6, in patients with PMR have been reported, but no elevation of IL-1ß or TNF-α was found in other reports1,2. Only IL-6 has been observed to be consistently high in patients with active disease4–6. IL-6 is recognized as the most sensitive indicator of disease activity and course and therefore IL-6 inhibition with tocilizumab may constitute a novel strategy for treatment of PMR. As for this case, computed tomography angiography showed that there was no simultaneous occurrence of giant cell arteritis (GCA) at the onset or during followup.

In the literature, the clinical relationship between PMR and GCA has been established, since 16%–21% of patients with PMR also had GCA, and PMR was reportedly present in 40%–60% of patients with GCA1. Several studies of cytokines in temporal artery biopsy sections of patients with GCA also revealed overexpression of IL-6 messenger RNA and protein2, indicating that IL-6 may play a role in the development of GCA as well as PMR. Although there have been no reports regarding treatment of GCA with tocilizumab, Nishimoto, et al found that treatment of a patient with Takayasu arteritis with tocilizumab improved the clinical manifestations and abnormal laboratory findings10. It is thus anticipated that tocilizumab may become a treatment option for GCA.

Although clinical studies are essential, for cases of PMR refractory to corticosteroids, treatment with tocilizumab can be considered a viable alternative.

Acknowledgments

We thank Dr. Atsushi Ogata, Dr. Masashi Narazaki, and Dr. Yoshihito Shima, Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University, for reviewing the manuscript.

Footnotes

  • Supported by the Program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation. Dr. T. Kishimoto holds a patent for tocilizumab.

REFERENCES

  1. 1.↵
    1. Salvarani C,
    2. Cantini F,
    3. Hunder GG
    . Polymyalgia rheumatica and giant-cell arthritis. Lancet 2008;372:234–45.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Martinez-Taboada VM,
    2. Alvarez L,
    3. RuizSoto M,
    4. Marin-Vidalled MJ,
    5. Lopez-Hoyos M
    . Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine 2008;44:207–20.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Salvarani C,
    2. Macchioni P,
    3. Manzini C,
    4. Paolazzi G,
    5. Trotta A,
    6. Manganelli P,
    7. et al.
    Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica. Ann Intern Med 2007;146:631–9.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Salvarani C,
    2. Cantini F,
    3. Niccoli L,
    4. Macchioni P,
    5. Consonni D,
    6. Bajocchi G,
    7. et al.
    Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica: a prospective followup study. Arthritis Rheum 2005;53:33–8.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Cutolo M,
    2. Montecucco CM,
    3. Cavagna L,
    4. Caporali R,
    5. Capellino S,
    6. Montagna P,
    7. et al.
    Serum cytokines and steroidal hormones in polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Ann Rheum Dis 2006;65:1438–43.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Alvarez-Rodriguez L,
    2. Lopez-Hoyos M,
    3. Mata C,
    4. Jose Marin M,
    5. Calvo-Alen J,
    6. Blanco R,
    7. et al.
    Circulating cytokines in active polymyalgia rheumatica. Ann Rheum Dis 2010;69:263–9.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Nishimoto N,
    2. Kishimoto T
    . Humanized antihuman IL-6 receptor antibody, tocilizumab. Handb Exp Pharmacol 2008;181:151–60.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Leeb BF,
    2. Bird HA
    . A disease activity score for polymyalgia rheumatica. Ann Rheum Dis 2004;63:1279–83.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Leeb BF,
    2. Rintelen B,
    3. Sautner J,
    4. Fassl C,
    5. Bird HA
    . The polymyalgia rheumatica activity score in daily use: proposal for a definition of remission. Arthritis Rheum 2007;57:810–5.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Nishimoto N,
    2. Nakahara H,
    3. Yoshio-Hoshino N,
    4. Mima T
    . Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008;58:1197–200.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 37, Issue 5
1 May 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica
KEISUKE HAGIHARA, ICHIRO KAWASE, TOSHIO TANAKA, TADAMITSU KISHIMOTO
The Journal of Rheumatology May 2010, 37 (5) 1075-1076; DOI: 10.3899/jrheum.091185

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Tocilizumab Ameliorates Clinical Symptoms in Polymyalgia Rheumatica
KEISUKE HAGIHARA, ICHIRO KAWASE, TOSHIO TANAKA, TADAMITSU KISHIMOTO
The Journal of Rheumatology May 2010, 37 (5) 1075-1076; DOI: 10.3899/jrheum.091185
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Duration of Steroid Therapy and Temporal Artery Biopsy Positivity in Giant Cell Arteritis: A Retrospective Cohort Study
  • Desk Rejections: Not Without Due Deliberation
  • COVID-19 and IgA Vasculitis
Show more Letters

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire